Recent reports show that c-Abl inhibitors are being used in clinical trials for different neurodegenerative pathologies, including Parkinson’s disease (Abushouk et al., 2018; Pagan et al., 2019) and other Dementias (Pagan et al., 2016), Huntington’s disease (Clinical trial gov identifier NCT03764215) and Alzheimer’s disease (NCT02947893) (Turner et al., 2020). The gene discussed is ABL1; the disease is dementia.